Recrudescence of a high parasitaemia, severe Plasmodium falciparum malaria episode, treated by artesunate monotherapy
نویسندگان
چکیده
A patient presenting with severe malaria, hyperparasitaemia, received 7-day artesunate monotherapy. recrudescence was detected and attributed to monotherapy a polyclonal infection without Kelch 13 gene mutation. second treatment artesunate, then quinine, followed by artemether-lumefantrine, successful.
منابع مشابه
Artesunate Dosing in Severe Falciparum Malaria
TO THE EDITOR—In the past 6 years the largest ever randomized controlled trials in severe falciparum malaria have been reported [1, 2]. Compared with quinine, parenteral artesunate reduced mortality by 22.5% (from 10.9% to 8.5%) in African children (N = 5425) and by 35% (from 22% to 15%) in Southeast Asian patients (N = 1461, of whom 202 were children). The artesunate dose evaluated in the AQUA...
متن کاملAssessing parasite clearance during uncomplicated Plasmodium falciparum infection treated with artesunate monotherapy in Suriname
BACKGROUND Artemisinin resistance in Plasmodium falciparum is suspected when the day 3 parasitemia is >10% when treated with artemisinin-based combination therapy or if >10% of patients treated with artemisinin-based combination therapy or artesunate monotherapy harbored parasites with half-lives ≥5 hours. Hence, a single-arm prospective efficacy trial was conducted in Suriname for uncomplicate...
متن کاملSevere Plasmodium falciparum malaria Malária grave por Plasmodium falciparum
Malaria is the world’s leading parasitic disease and affects approximately 40% of the world’s population (approximately 2.4 billion people) in more than 100 countries.(1) The disease, that is caused for Plamodium spp., particularly affects populations in tropical and subtropical areas, especially in developing and underdeveloped countries. Brazil has the largest number of cases on the American ...
متن کاملComparison of artesunate and quinine in the treatment of Sudanese children with severe Plasmodium falciparum malaria.
Sixty-six children presenting to Singa hospital, Sudan with different manifestations of severe Plasmodium falciparum malaria were randomly divided into two well-matched groups (33 in each arm) to receive either intravenous artesunate 2·4 mg/kg at 0, 12, and 24 hours, then daily, or intravenous quinine 20mg/kg initially then 10mg/kg three times a day. There was no significant difference in the f...
متن کاملArtesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria
BACKGROUND The World Health Organization (WHO) recommends that people with uncomplicated Plasmodium falciparum malaria are treated using Artemisinin-based Combination Therapy (ACT). ACT combines three-days of a short-acting artemisinin derivative with a longer-acting antimalarial which has a different mode of action. Pyronaridine has been reported as an effective antimalarial over two decades o...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: International Journal of Infectious Diseases
سال: 2021
ISSN: ['1878-3511', '1201-9712']
DOI: https://doi.org/10.1016/j.ijid.2021.02.080